---
title: "CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293923275.md"
description: "A clinical trial is being planned to evaluate a groundbreaking intervention for patients with SYNGAP1-related disorder. This trial will mark the first time the intervention is tested in humans, aiming to determine its effectiveness in modifying the course of the disease. SYNGAP1-related disorder affects approximately [insert number] individuals worldwide and currently lacks effective treatment options. The trial holds promise for potentially improving the quality of life for patients with this rare genetic disorder."
datetime: "2026-07-27T11:03:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293923275.md)
  - [en](https://longbridge.com/en/news/293923275.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293923275.md)
generator: "portal-rs"
---

# CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder

A clinical trial is being planned to evaluate a groundbreaking intervention for patients with SYNGAP1-related disorder. This trial will mark the first time the intervention is tested in humans, aiming to determine its effectiveness in modifying the course of the disease. SYNGAP1-related disorder affects approximately \[insert number\] individuals worldwide and currently lacks effective treatment options. The trial holds promise for potentially improving the quality of life for patients with this rare genetic disorder.

### Related Stocks

- [CAMP.US](https://longbridge.com/en/quote/CAMP.US.md)

## Related News & Research

- [CAMP4 wins Australia clearance to start Phase 1/2 trial of CMP-002 in SYNGAP1 disorder](https://longbridge.com/en/news/294149424.md)
- [Camp4 wins Australian clearance for Phase 1/2 CMP-002 trial in SYNGAP1-related disorder](https://longbridge.com/en/news/293921311.md)
- [Tyra Biosciences reports 79% response rate in Phase 2 bladder cancer study of dabogratinib at 60 mg dose](https://longbridge.com/en/news/298445177.md)
- [TENX: Levosimendan benefits PH-HFpEF patients with high disease burden, guiding a refined LEVEL-2 trial](https://longbridge.com/en/news/298456291.md)
- [VRTX: Upcoming renal and pain launches, pivotal data, and global expansion drive growth outlook](https://longbridge.com/en/news/298508921.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**